CN103833736A - Method for preparing avanafil - Google Patents
Method for preparing avanafil Download PDFInfo
- Publication number
- CN103833736A CN103833736A CN201410075978.4A CN201410075978A CN103833736A CN 103833736 A CN103833736 A CN 103833736A CN 201410075978 A CN201410075978 A CN 201410075978A CN 103833736 A CN103833736 A CN 103833736A
- Authority
- CN
- China
- Prior art keywords
- chloro
- preparation
- methylthiopyrimidine
- method described
- methoxy benzylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a method for preparing avanafil. The method is characterized by comprising the step of enabling 4-(3-chloro-4-methoxybenzylamino)-5-ethoxycarbonyl-2-methylthiopyrimidine to be subjected to hydrolysis, condensation, oxidation and substitution reaction sequentially, thereby preparing avanafil. The method has the advantages of being simple and convenient in operation, easy in product quality control, high in reaction yield, high in product purity, low in cost and applicable to industrial production and the like.
Description
Technical field
the present invention relates to compound preparing technical field, be specifically related to the preparation method of avanaphil.
Background technology
avanaphil (Avanafil, structure is suc as formula shown in I), i.e. (S)-4-(3-chloro-4-methoxy benzyl amino)-2-(2-methylol-1-pyrrolidyl)-N-(2-pyrimidine methyl)-5-pyrimidine carboxamide), a kind of oral quick-acting highly selective phosphodiesterase-5(PDEV) inhibitor, there is the internal metabolism that suppresses cyclic guanosine monophosphate, the diastole effect of strengthening unstriated muscle, increase the volume of blood flow of penis, help the effects such as erection, for prevention or treatment erectile disfunction (ED), and be that in similar drugs, onset is the fastest, the medicine of side effect minimum.Avanaphil is in 2012 through U.S. FDA approval listing, and commodity are called Stendra.
disclose the preparation method of avanaphil and analogue thereof with WO0119802A, comprised the steps:
1) the chloro-2-methylthiopyrimidine-5-ethyl formate of 4-and 3-chloro-4-methoxy benzylamine generation substitution reaction, make 4-(3-chloro-4-methoxy benzylamino)-5-ethoxy carbonyl-2-methylthiopyrimidine;
2) by 4-(3-chloro-4-methoxy benzylamino)-5-ethoxy carbonyl-2-methylthiopyrimidine carries out oxidizing reaction, makes 4-(3-chloro-4-methoxy benzylamino)-5-ethoxy carbonyl-2-methylsulfinyl pyrimidine;
3) by 4-(3-chloro-4-methoxy benzylamino)-5-ethoxy carbonyl-2-methylsulfinyl pyrimidine and L-dried meat ammonia alcohol generation substitution reaction, obtain (S)-4-(3-chloro-4-methoxy benzylamino)-5-ethoxy carbonyl-2-(2-methylol-1-pyrrolidyl) pyrimidine;
4) by (S)-4-(3-chloro-4-methoxy benzylamino)-5-ethoxy carbonyl-2-(2-methylol-1-pyrrolidyl) the pyrimidine reaction that is hydrolyzed, make (S)-4-(3-chloro-4-methoxy benzylamino)-5-carboxyl-2-(2-methylol-1-pyrrolidyl) pyrimidine;
5) by (S)-4-(3-chloro-4-methoxy benzylamino)-5-carboxyl-2-(2-methylol-1-pyrrolidyl) pyrimidine and 2-amino methylpyrimidine carry out condensation reaction, obtains avanaphil.
two intermediates (4-(3-chloro-4-methoxy benzylamino)-5-ethoxy carbonyl-2-methylthiopyrimidine that the method makes and (S)-4-(3-chloro-4-methoxy benzylamino)-5-ethoxy carbonyl-2-(2-methylol-1-pyrrolidyl) fusing point of pyrimidine is respectively 85-86 ℃ and 88-90 ℃, exist fusing point low, be difficult for solidifying and purifying, quality product are difficult to the defects such as assurance; And after introducing chirality fragment, step 3) carries out again alkaline hydrolysis, thus there is the risk of chiral centre racemization, and then affect purity, yield and the manufacturing cost (cost is high) of product.
4-(3-chloro-4-methoxy benzylamino is disclosed) preparation method of-5-ethoxy carbonyl-2-methylthiopyrimidine, comprise the steps: 1) under ice-cooled, to the N of 4-chloro-5-ethoxy carbonyl-2-methylthiopyrimidine (25.33g), in dinethylformamide (85mL) solution, add the solution of 3-chloro-4-methoxy benzyl amine (19.62g) in DMF solution (15ml) and triethylamine (16.7ml); 2) at room temperature, stir this mixture 20 minutes, add 3-chloro-4-methoxy benzyl amine (940mg), then stir the mixture 15 minutes; 3) in this mixture, add said amine (940mg) again, stir this mixture 15 minutes; 4) reaction mixture is poured in the mixture of frozen water and citric acid, be extracted with ethyl acetate mixture, use successively 10% aqueous citric acid solution, water and salt water washing extraction liquid, pass through anhydrous sodium sulfate drying; 5) under reduced pressure boil off solvent, with normal hexane wash residual thing, obtain 4-(3-chloro-4-methoxy benzylamino)-5-ethoxy carbonyl-2-methylthiopyrimidine (38.34g), 86 ℃ of fusing points.
for this reason, need to study new avanaphil preparation method to solve aforementioned technical problem.The disclosed content of aforementioned documents is all as the application's Technical Reference.
Summary of the invention
the preparation method who the object of the present invention is to provide a kind of avanaphil, is characterized in that, by 4-(3-chloro-4-methoxy benzylamino)-5-ethoxy carbonyl-2-methylthiopyrimidine is hydrolyzed successively, condensation, oxidation, substitution reaction, makes avanaphil.
in the preferred technical solution of the present invention, described hydrolysis reaction is, by 4-(3-chloro-4-methoxy benzylamino)-5-ethoxy carbonyl-2-methylthiopyrimidine is placed in basic solution hydrolysis reaction occurs, and makes 4-(3-chloro-4-methoxy benzylamino)-5-carboxyl-2-methylthiopyrimidine.
in the preferred technical solution of the present invention; described condensation reaction is; by 4-(3-chloro-4-methoxy benzylamino)-5-carboxyl-2-methylthiopyrimidine and 2-amino methylpyrimidine in solvent with condensing agent generation condensation reaction, make 4-(3-chloro-4-methoxy benzylamino)-5-[N-(2-Pyrimidylmethyl) formamyl]-2-methylthiopyrimidine.
in the preferred technical solution of the present invention; described oxidizing reaction is; by 4-(3-chloro-4-methoxy benzylamino)-5-[N-(2-Pyrimidylmethyl) formamyl]-2-methylthiopyrimidine and oxygenant generation oxidizing reaction, make 4-(3-chloro-4-methoxy benzylamino)-5-[N-(2-Pyrimidylmethyl) formamyl]-2-methylsulfinyl pyrimidine.
in the preferred technical solution of the present invention; described substitution reaction is for by 4-(3-chloro-4-methoxy benzylamino)-5-[N-(2-Pyrimidylmethyl) formamyl] there is substitution reaction in-2-methylsulfinyl pyrimidine and L-dried meat ammonia alcohol, make avanaphil under the effect of acid binding agent.
in the preferred technical solution of the present invention, the alkaline matter that forms basic solution in hydrolysis reaction is selected from any or its combination of lithium hydroxide, sodium hydroxide, potassium hydroxide, potassium tert.-butoxide, is preferably any or its combination of sodium hydroxide, potassium hydroxide.
in the preferred technical solution of the present invention, hydrolysising reacting temperature is 20-100 ℃, is preferably 30-80 ℃.
in the preferred technical solution of the present invention, solvent in condensation reaction is selected from methylene dichloride, acetonitrile, tetrahydrofuran (THF), N, any or its combination of dinethylformamide, dimethyl sulfoxide (DMSO), tetramethylene sulfone, hexamethylphosphoramide, be preferably any or its combination of methylene dichloride or DMF.
in the preferred technical solution of the present invention, the chloro-4-methyl-benzyl of the 4-(3-amino in condensation reaction) molar ratio of-5-carboxyl-2-methylthiopyrimidine and 2-amino methylpyrimidine is 1:1-1:2.5, is preferably 1:1.5-1:2.0.
in the preferred technical solution of the present invention, described condensing agent is selected from N, N-dicyclohexylcarbodiimide (DCC), N, N-DIC (DIC), 1-(3-dimethylamino-propyl)-3-ethyl-carbodiimide hydrochloride (EDCI), O-(7-azepine benzotriazole)-N, N, N ', in N '-tetramethyl-urea phosphofluoric acid ester (HATU), Vinyl chloroformate, the chloroformic acid tert-butyl ester, thionyl chloride, oxalyl chloride any or its combination, be preferably 1-(3-dimethylamino-propyl)-3-ethyl-carbodiimide hydrochloride (EDCI).
in the preferred technical solution of the present invention, 4-(3-chloro-4-methoxy benzylamino in condensation reaction) molar ratio of-5-carboxyl-2-methylthiopyrimidine and condensing agent is 1:1.0-1:2.0, is preferably 1:1.2-1:1.5.
in the preferred technical solution of the present invention, setting-up point is 0-100 ℃, is preferably 10-60 ℃.
in the preferred technical solution of the present invention, described oxygenant is selected from hydrogen peroxide, tertbutyl peroxide, metachloroperbenzoic acid, clorox, acetic acid iodobenzene (PhI (OAc)
2
) in any or its combination, be preferably metachloroperbenzoic acid.
in the preferred technical solution of the present invention, 4-(3-chloro-4-methoxy benzylamino)-5-[N-(2-Pyrimidylmethyl) formamyl] molar ratio of-2-methylthiopyrimidine and oxygenant is 1:1-1:5, is preferably 1:1-1:3.
in the preferred technical solution of the present invention, oxidizing reaction temperature is-20-60 ℃ to be preferably-10-10 ℃.
in the preferred technical solution of the present invention; 4-(3-chloro-4-methoxy benzylamino in substitution reaction)-5-[N-(2-Pyrimidylmethyl) formamyl] molar ratio of-2-methylsulfinyl pyrimidine and L-dried meat ammonia alcohol is 1:1.0-1:1.5, is preferably 1:1.0-1:1.3.
in the preferred technical solution of the present invention, described acid binding agent is selected from any or its combination of sodium carbonate, salt of wormwood, sodium bicarbonate, saleratus, triethylamine, diisopropylethylamine, pyridine, is preferably any or its combination of triethylamine or diisopropylethylamine.
another object of the present invention is to provide a kind of midbody compound, described intermediate is selected from 4-(3-chloro-4-methoxy benzylamino)-5-[N-(2-Pyrimidylmethyl) formamyl]-2-methylthiopyrimidine, 4-(3-chloro-4-methoxy benzylamino)-5-[N-(2-Pyrimidylmethyl) formamyl] any of-2-methylsulfinyl pyrimidine.
the chemical name of intermediate 1-3 of the present invention is:
intermediate 1:4-(3-chloro-4-methoxy benzylamino)-5-carboxyl-2-methylthiopyrimidine;
intermediate 2:4-(3-chloro-4-methoxy benzylamino)-5-[N-(2-Pyrimidylmethyl) formamyl]-2-methylthiopyrimidine;
intermediate 3:4-(3-chloro-4-methoxy benzylamino)-5-[N-(2-Pyrimidylmethyl) formamyl]-2-methylsulfinyl pyrimidine.
except as otherwise noted, while the present invention relates to the per-cent between liquid and liquid, described per-cent is volume/volume per-cent; While the present invention relates to the per-cent between liquid and solid, described per-cent is volume/weight per-cent; While the present invention relates to the per-cent between solid and liquid, described per-cent is weight/volume percent; All the other are weight/weight percent.
compared with prior art, the preparation method of avanaphil of the present invention has following beneficial effect:
1, the present invention is by 4-(3-chloro-4-methoxy benzylamino)-5-ethoxy carbonyl-2-methylthiopyrimidine is hydrolyzed successively, condensation, oxidation, substitution reaction, make avanaphil, by adjusting reaction sequence, improve fusing point and the physicochemical property of intermediate, the each intermediate making in preparation process is solid and without chirality, be easy to purifying and detection, also avoid the risk of chiral intermediate racemization, effectively solve the problem such as purification of intermediate and chiral centre racemization, quality product and yield are improved, simplify the recycling program of intermediate and the three wastes thereof, significantly reduce production cost.
, avanaphil of the present invention preparation method have that easy and simple to handle, quality product is easy to control, reaction yield is high, impurity is few, product purity is high, cost is low, be applicable to the advantages such as suitability for industrialized production.
Accompanying drawing explanation
the disclosed avanaphil preparation technology of Fig. 1 document WO0183460A and WO0119802A flow process;
preparation technology's flow process of Fig. 2 avanaphil of the present invention.
Embodiment
illustrate the present invention below with reference to embodiment, embodiments of the invention are only for technical scheme of the present invention is described, and non-limiting essence of the present invention.
embodiment 1the preparation of avanaphil
the preparation method of avanaphil, comprises the steps:
1) preparation of intermediate 1: by 4-(3-chloro-4-methoxy benzylamino)-5-ethoxy carbonyl-2-methylthiopyrimidine (5g) is dissolved in ethanol (15ml), adds purified water (5ml) and sodium hydroxide (1.1g), return stirring 1 hour; After TLC monitors and disappears to raw material, concentrating under reduced pressure ethanol is to dry, regulates pH6-7 with concentrated hydrochloric acid, separates out suction filtration after solid, collects solid drying, makes intermediate 1(4.2g), yield 90%;
2) preparation of intermediate 2: under room temperature, by 4-(3-chloro-4-methoxy benzylamino)-5-carboxyl-2-methylthiopyrimidine (4.0g), 2-amino methylpyrimidine (2.2g), EDCI(2.8g) and N-hydroxy benzo triazole (1.9g) join DMF(40 mL) in, stir 10 hours; TLC detects extremely after completion of the reaction, reaction solution is poured into water, be extracted with ethyl acetate, merge organic phase, successively with saturated aqueous common salt, saturated sodium bicarbonate solution washing, after anhydrous sodium sulfate drying, filter, filtrate decompression is concentrated, after residue recrystallization, make intermediate 2(4.3g), yield 85%;
3) preparation of intermediate 3: at 0 ℃, at 4-(3-chloro-4-methoxy benzylamino)-5-[N-(2-Pyrimidylmethyl) formamyl] add metachloroperbenzoic acid (2.5g) in methylene dichloride (50ml) solution of-2-methylthiopyrimidine (4g), stir 2 hours; For reaction solution, after saturated sodium bicarbonate solution, saturated common salt water washing, anhydrous sodium sulfate drying, filters, and after concentrating under reduced pressure reaction solution, makes intermediate 3(3.8g), yield 92%;
4) preparation of avanaphil: at 0 ℃, by 4-(3-chloro-4-methoxy benzylamino)-5-[N-(2-Pyrimidylmethyl) formamyl]-2-methylsulfinyl pyrimidine (3g) and triethylamine (0.8g) be dissolved in THF(40mL) in, add L-dried meat ammonia alcohol (0.8g); Stirring at room temperature 2 hours, TLC monitoring to reaction finishes; Concentrating under reduced pressure reaction solution, adds ethyl acetate and water, layering, and organic phase saturated common salt water washing, after anhydrous sodium sulfate drying, filters, and filtrate decompression is concentrated, and enriched material, through recrystallizing methanol, makes white powder avanaphil 2.9g, yield 91%.
embodiment 2the preparation of avanaphil
the preparation method of avanaphil, comprises the steps:
1) preparation of intermediate 1: by 4-(3-chloro-4-methoxy benzylamino)-5-ethoxy carbonyl-2-methylthiopyrimidine (4g) is dissolved in ethanol (12ml), adds purified water (4ml) and potassium hydroxide (1.2g), and 40 ℃ are stirred 10 hours.After TLC monitors and disappears to raw material, concentrating under reduced pressure ethanol is to dry, regulates pH6-7 with concentrated hydrochloric acid, separates out suction filtration after solid, collects solid drying, makes intermediate 1(3.4g), yield 92%;
2) preparation of intermediate 2: under room temperature, by 4-(3-chloro-4-methoxy benzylamino)-5-carboxyl-2-methylthiopyrimidine (4.0g) is added in thionyl chloride (30mL), back flow reaction 2 hours, be evaporated to dry, in resistates, add after methylene dichloride dissolving, add again 2-amino methylpyrimidine (2.2g) and triethylamine (2.2g), after stirring at room temperature 2 hours, water, saturated common salt water washing successively, after anhydrous sodium sulfate drying, filters, concentrating under reduced pressure, dry, make intermediate 2(4.0g), yield 80%;
3) preparation of intermediate 3: at-10 ℃; at 4-(3-chloro-4-methoxy benzylamino)-5-[N-(2-Pyrimidylmethyl) formamyl] add metachloroperbenzoic acid (4.2g) in trichloromethane (20ml) solution of-2-methylthiopyrimidine (4g), stir 4 hours.For reaction solution, after saturated sodium bicarbonate solution, saturated common salt water washing, anhydrous sodium sulfate drying, filters, and after concentrating under reduced pressure reaction solution, makes intermediate 3(3.3g), yield 79%;
4) preparation of avanaphil: under room temperature, by 4-(3-chloro-4-methoxy benzylamino)-5-[N-(2-Pyrimidylmethyl) formamyl]-2-methylsulfinyl pyrimidine (3g) and diisopropyl ethyl amine (1g) be dissolved in methylene dichloride (40mL), adds L-dried meat ammonia alcohol (0.8g); Stirring at room temperature 2 hours, TLC monitors reaction.After reaction finishes, organic phase water, saturated common salt water washing, after anhydrous sodium sulfate drying, filter, and filtrate decompression is concentrated, and enriched material, through recrystallizing methanol, makes white powder avanaphil 3.0g, yield 92%.
embodiment 3the preparation of avanaphil
the preparation method of avanaphil, comprises the steps:
1) preparation of intermediate 1: by 4-(3-chloro-4-methoxy benzylamino)-5-ethoxy carbonyl-2-methylthiopyrimidine (5g) is dissolved in ethanol (15ml), adds purified water (5ml) and lithium hydroxide (0.6g), return stirring 4 hours.After TLC monitors and disappears to raw material, concentrating under reduced pressure ethanol is to dry, regulates pH6-7 with concentrated hydrochloric acid, separates out suction filtration after solid, collects solid drying, makes intermediate 1(4.3g), yield 92%;
2) preparation of intermediate 2: at 0 ℃, at 4-(3-chloro-4-methoxy benzylamino) add triethylamine (0.9g) and Vinyl chloroformate (0.96g) in methylene dichloride (20mL) solution of-5-carboxyl-2-methylthiopyrimidine (2.0g), stirring at room temperature 5 hours, after TLC monitors and disappears to raw material, then add triethylamine (1.1g) and 2-amino methylpyrimidine (1.1g); After stirring at room temperature 10 hours, in reaction solution, add water, layering, gets organic phase, then water, saturated common salt water washing, after anhydrous sodium sulfate drying, filters, and filtrate decompression is concentrated, makes intermediate 2(2.0g), yield 81%;
3) preparation of intermediate 3: under room temperature, to 4-(3-chloro-4-methoxy benzylamino)-5-[N-(2-Pyrimidylmethyl) formamyl] two chlorine solution (20ml) of-2-methylthiopyrimidine (4g) add clorox (2.6g), stir 10 hours.For reaction solution, after saturated sodium bicarbonate solution, saturated common salt water washing, anhydrous sodium sulfate drying, filters, and after concentrating under reduced pressure, makes intermediate 3(3.0g), yield 74%;
4) preparation of avanaphil: at 0 ℃, by 4-(3-chloro-4-methoxy benzylamino)-5-[N-(2-Pyrimidylmethyl) formamyl]-2-methylsulfinyl pyrimidine (3g) and Anhydrous potassium carbonate (1g) join in acetonitrile (40mL), add again L-dried meat ammonia alcohol (0.8g), stirring at room temperature 4 hours, after TLC monitoring to reaction finishes, concentrating under reduced pressure, add ethyl acetate and water, layering, organic phase saturated common salt water washing, after anhydrous sodium sulfate drying, filter, filtrate decompression is concentrated, enriched material is through recrystallizing methanol, make white powder avanaphil 3.0g, yield 92%.
table 1
Claims (18)
1. a preparation method for avanaphil, is characterized in that, by 4-(3-chloro-4-methoxy benzylamino)-5-ethoxy carbonyl-2-methylthiopyrimidine is hydrolyzed successively, condensation, oxidation, substitution reaction, makes avanaphil.
2. preparation method according to claim 1, described hydrolysis reaction is, by 4-(3-chloro-4-methoxy benzylamino)-5-ethoxy carbonyl-2-methylthiopyrimidine is placed in basic solution hydrolysis reaction occurs, and makes 4-(3-chloro-4-methoxy benzylamino)-5-carboxyl-2-methylthiopyrimidine.
3. preparation method according to claim 1 and 2; described condensation reaction is; by 4-(3-chloro-4-methoxy benzylamino)-5-carboxyl-2-methylthiopyrimidine and 2-amino methylpyrimidine in solvent with condensing agent generation condensation reaction, make 4-(3-chloro-4-methoxy benzylamino)-5-[N-(2-Pyrimidylmethyl) formamyl]-2-methylthiopyrimidine.
4. according to the preparation method described in claim 1-3 any one; described oxidizing reaction is; by 4-(3-chloro-4-methoxy benzylamino)-5-[N-(2-Pyrimidylmethyl) formamyl]-2-methylthiopyrimidine and oxygenant generation oxidizing reaction, make 4-(3-chloro-4-methoxy benzylamino)-5-[N-(2-Pyrimidylmethyl) formamyl]-2-methylsulfinyl pyrimidine.
5. according to the preparation method described in claim 1-4 any one; described substitution reaction is for by 4-(3-chloro-4-methoxy benzylamino)-5-[N-(2-Pyrimidylmethyl) formamyl] there is substitution reaction in-2-methylsulfinyl pyrimidine and L-dried meat ammonia alcohol, make avanaphil under the effect of acid binding agent.
6. according to the preparation method described in claim 1-5 any one, the alkaline matter that forms basic solution in described hydrolysis reaction is selected from any or its combination of lithium hydroxide, sodium hydroxide, potassium hydroxide, potassium tert.-butoxide, is preferably any or its combination of sodium hydroxide, potassium hydroxide.
7. according to the preparation method described in claim 1-6 any one, described hydrolysising reacting temperature is 20-100 ℃, is preferably 30-80 ℃.
8. according to the preparation method described in claim 1-7 any one, solvent in condensation reaction is selected from methylene dichloride, acetonitrile, tetrahydrofuran (THF), N, any or its combination of dinethylformamide, dimethyl sulfoxide (DMSO), tetramethylene sulfone, hexamethylphosphoramide, be preferably any or its combination of methylene dichloride or DMF.
9. according to the preparation method described in claim 1-8 any one, 4-(3-chloro-4-methoxy benzylamino in condensation reaction) molar ratio of-5-carboxyl-2-methylthiopyrimidine and 2-amino methylpyrimidine is 1:1-1:2.5, is preferably 1:1.5-1:2.0.
10. according to the preparation method described in claim 1-9 any one, described condensing agent is selected from N, N-dicyclohexylcarbodiimide (DCC), N, N-DIC (DIC), 1-(3-dimethylamino-propyl)-3-ethyl-carbodiimide hydrochloride (EDCI), O-(7-azepine benzotriazole)-N, N, N ', N '-tetramethyl-urea phosphofluoric acid ester (HATU), Vinyl chloroformate, the chloroformic acid tert-butyl ester, thionyl chloride, any in oxalyl chloride or its combination, be preferably 1-(3-dimethylamino-propyl)-3-ethyl-carbodiimide hydrochloride (EDCI).
11. according to the preparation method described in claim 1-10 any one, 4-(3-chloro-4-methoxy benzylamino in condensation reaction) molar ratio of-5-carboxyl-2-methylthiopyrimidine and condensing agent is 1:1.0-1:2.0, is preferably 1:1.2-1:1.5.
12. according to the preparation method described in claim 1-11 any one, and setting-up point is 0-100 ℃, is preferably 10-60 ℃.
13. according to the preparation method described in claim 1-12 any one, and described oxygenant is selected from hydrogen peroxide, tertbutyl peroxide, metachloroperbenzoic acid, clorox, acetic acid iodobenzene (PhI (OAc)
2) in any or its combination, be preferably metachloroperbenzoic acid.
14. according to the preparation method described in claim 1-13 any one, 4-(3-chloro-4-methoxy benzylamino)-5-[N-(2-Pyrimidylmethyl) formamyl] molar ratio of-2-methylthiopyrimidine and oxygenant is 1:1-1:5, is preferably 1:1-1:3.
15. according to the preparation method described in claim 1-14 any one, and oxidizing reaction temperature is-20-60 ℃ to be preferably-10-10 ℃.
16. according to the preparation method described in claim 1-15 any one; 4-(3-chloro-4-methoxy benzylamino in substitution reaction)-5-[N-(2-Pyrimidylmethyl) formamyl] molar ratio of-2-methylsulfinyl pyrimidine and L-dried meat ammonia alcohol is 1:1.0-1:1.5, is preferably 1:1.0-1:1.3.
17. according to the preparation method described in claim 1-16 any one, described acid binding agent is selected from any or its combination of sodium carbonate, salt of wormwood, sodium bicarbonate, saleratus, triethylamine, diisopropylethylamine, pyridine, is preferably any or its combination of triethylamine or diisopropylethylamine.
18. 1 kinds of midbody compounds, described intermediate is selected from 4-(3-chloro-4-methoxy benzylamino)-5-[N-(2-Pyrimidylmethyl) formamyl]-2-methylthiopyrimidine, 4-(3-chloro-4-methoxy benzylamino)-5-[N-(2-Pyrimidylmethyl) formamyl] any of-2-methylsulfinyl pyrimidine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410075978.4A CN103833736A (en) | 2014-03-04 | 2014-03-04 | Method for preparing avanafil |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410075978.4A CN103833736A (en) | 2014-03-04 | 2014-03-04 | Method for preparing avanafil |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103833736A true CN103833736A (en) | 2014-06-04 |
Family
ID=50797673
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410075978.4A Pending CN103833736A (en) | 2014-03-04 | 2014-03-04 | Method for preparing avanafil |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103833736A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104530017A (en) * | 2015-01-05 | 2015-04-22 | 南京晓庄学院 | Avanafil preparation method |
| CN104628709A (en) * | 2015-02-05 | 2015-05-20 | 合肥创新医药技术有限公司 | Preparation method of avanafil |
| CN104710411A (en) * | 2015-03-13 | 2015-06-17 | 安润医药科技（苏州）有限公司 | Synthesis method of avanafil |
| CN109280050A (en) * | 2018-09-25 | 2019-01-29 | 重庆奥舍生物化工有限公司 | A kind of preparation method of pharmaceutical compound avanaphil |
| CN109553607A (en) * | 2017-09-25 | 2019-04-02 | 镇江圣安医药有限公司 | Pyrimidine carboxamide derivatives and preparation method thereof, composition, preparation and purposes |
| CN109696502A (en) * | 2019-02-22 | 2019-04-30 | 重庆安格龙翔医药科技有限公司 | Benzene and the remaining method of Mesityl oxide in gas chromatographic detection avanaphil |
| CN114280174A (en) * | 2021-12-07 | 2022-04-05 | 嘉实（湖南）医药科技有限公司 | Detection method of avanafil and related impurities thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001019802A1 (en) * | 1999-09-16 | 2001-03-22 | Tanabe Seiyaku Co., Ltd. | Aromatic nitrogenous six-membered ring compounds |
| CN102372697A (en) * | 2010-08-19 | 2012-03-14 | 山东轩竹医药科技有限公司 | Substituted miazines compound |
| CN104059025A (en) * | 2013-03-20 | 2014-09-24 | 广州朗圣药业有限公司 | Novel intermediate used for preparation of avanafil and preparation method thereof |
-
2014
- 2014-03-04 CN CN201410075978.4A patent/CN103833736A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001019802A1 (en) * | 1999-09-16 | 2001-03-22 | Tanabe Seiyaku Co., Ltd. | Aromatic nitrogenous six-membered ring compounds |
| CN102372697A (en) * | 2010-08-19 | 2012-03-14 | 山东轩竹医药科技有限公司 | Substituted miazines compound |
| CN104059025A (en) * | 2013-03-20 | 2014-09-24 | 广州朗圣药业有限公司 | Novel intermediate used for preparation of avanafil and preparation method thereof |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104530017A (en) * | 2015-01-05 | 2015-04-22 | 南京晓庄学院 | Avanafil preparation method |
| CN104628709A (en) * | 2015-02-05 | 2015-05-20 | 合肥创新医药技术有限公司 | Preparation method of avanafil |
| CN104710411A (en) * | 2015-03-13 | 2015-06-17 | 安润医药科技（苏州）有限公司 | Synthesis method of avanafil |
| CN109553607A (en) * | 2017-09-25 | 2019-04-02 | 镇江圣安医药有限公司 | Pyrimidine carboxamide derivatives and preparation method thereof, composition, preparation and purposes |
| CN109280050A (en) * | 2018-09-25 | 2019-01-29 | 重庆奥舍生物化工有限公司 | A kind of preparation method of pharmaceutical compound avanaphil |
| CN109280050B (en) * | 2018-09-25 | 2021-01-29 | 重庆奥舍生物化工有限公司 | Preparation method of medical compound avanafil |
| CN109696502A (en) * | 2019-02-22 | 2019-04-30 | 重庆安格龙翔医药科技有限公司 | Benzene and the remaining method of Mesityl oxide in gas chromatographic detection avanaphil |
| CN114280174A (en) * | 2021-12-07 | 2022-04-05 | 嘉实（湖南）医药科技有限公司 | Detection method of avanafil and related impurities thereof |
| CN114280174B (en) * | 2021-12-07 | 2023-12-29 | 嘉实（湖南）医药科技有限公司 | Detection method of avanafil and related impurities thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103833736A (en) | Method for preparing avanafil | |
| CA2840818A1 (en) | An improved process for the preparation of azilsartan medoxomil | |
| JP2013532164A (en) | Methods for preparing thrombin specific inhibitors | |
| WO2010045900A1 (en) | A method for the preparation of dabigatran and its intermediates | |
| TW201906826A (en) | Synthesis of Omeka for Mokabir | |
| JP5403205B2 (en) | Process for producing 2-amino-N- (2,2,2-trifluoroethyl) acetamide compound or a salt thereof | |
| KR101098116B1 (en) | Improved process for preparing rebamipide | |
| JP2017088632A (en) | Compounds useful in the synthesis of benzamide compounds | |
| CA2619955A1 (en) | Process for preparing valsartan | |
| WO2014020555A2 (en) | An improved process for the preparation of dabigatran etexilate mesylate | |
| CN104447685A (en) | Preparation method of alogliptin | |
| ES2791187T3 (en) | Dabigatran synthesis | |
| CN105753944A (en) | Preparation intermediate for daclatasvir and derivatives thereof | |
| CN101362729B (en) | Valsartan postprocessing method | |
| WO2009086728A1 (en) | Mothed for preparing repaglinide | |
| WO2018210354A1 (en) | Novel preparation method for anti-gout drug lesinurad, and key intermediate thereof | |
| CN105315256A (en) | Industrialization-suitable preparation method of high-purity trelagliptin succinate | |
| CN107540656B (en) | Preparation method of alogliptin benzoate | |
| CN103130700B (en) | Preparation method of azelnidipine intermediate | |
| CN103435526B (en) | Synthesis method of vildagliptin | |
| CN103724248B (en) | The preparation method of vildagliptin process contaminants | |
| KR20100021433A (en) | Process for preparing valsartan | |
| CN107722007B (en) | Preparation method of apixaban impurity | |
| TW200913995A (en) | Process for the preparation of benzimidazol thienylamine compounds and derivatives thereof useful as sodium/proton exchanger type 3 inhibitors | |
| CN105418580A (en) | New trelagliptin preparation process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140604 |